Monograph Capital Partners — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
UroGen PharmaNASDAQ: URGNJul 2023
A US-headquartered biotech company developing innovative solutions for urothelial and specialty cancers using RTGel hydrogel technology (exited July 2025).
BiotechPrinceton, US
Stuart Holden, M.D.(Director)Jason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Fred Cohen, M.D.(Director)Don Kim(Executive Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.